Immunotherapy Induces Responses in Subtypes of Sarcomas

March 28, 2020

Jonathan C. Trent, MD, PhD, discusses some of the recent immunotherapeutic advances in the treatment landscape for patients with sarcoma, particularly with immune checkpoint inhibitors.

Jonathan C. Trent, MD, PhD, a professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses some of the recent immunotherapeutic advances in the treatment landscape for patients with sarcoma, particularly with immune checkpoint inhibitors.

Angiosarcoma appears responsive to immune checkpoint inhibitors, says Trent. A study published in theJournal for Immunotherapy of Cancer, immune checkpoint inhibitors resulted in an approximate 70% complete or partial response rate in patients withangiosarcoma.

Trent notes that patients with cutaneous angiosarcoma appear to have the most benefit from immunotherapy. However, pleomorphic sarcoma and the differentiated liposarcoma still have a lot of progress to be made in terms of bringing immunotherapy into the day-to-day management of patients with soft tissue sarcoma.

<< View more resources and information regarding sarcoma